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Abstract
Background: Intracellular free calcium ([Ca2+]i) is a key element in apoptotic signaling and a
number of calcium-dependent apoptosis pathways have been described. We here used a chemical
biology strategy to elucidate the relative importance of such different pathways.
Results: A set of 40 agents ("bioprobes") that induce apoptosis was first identified by screening of
a chemical library. Using p53, AP-1, NFAT and NF-κB reporter cell lines, these bioprobes were
verified to induce different patterns of signaling. Experiments using the calcium chelator BAPTA-
AM showed that Ca2+ was involved in induction of apoptosis by the majority of the bioprobes and
that Ca2+ was in general required several hours into the apoptosis process. Further studies showed
that the calmodulin pathway was an important mediator of the apoptotic response. Inhibition of
calmodulin kinase II (CaMKII) resulted in more effective inhibition of apoptosis compared to
inhibition of calpain, calcineurin/PP2B or DAP kinase. We used one of the bioprobes, the plant
alkaloid helenalin, to study the role of CaMKII in apoptosis. Helenalin induced CaMKII, ASK1 and
Jun-N-terminal kinase (JNK) activity, and inhibition of these kinases inhibited apoptosis.
Conclusion: Our study shows that calcium signaling is generally not an early event during the
apoptosis process and suggests that a CaMKII/ASK1 signaling mechanism is important for sustained
JNK activation and apoptosis by some types of stimuli.
Background
Calcium (Ca2+) is a universal signaling molecule regulat-
ing many aspects of cellular function and is one of the key
elements of apoptotic signaling pathways [1]. Some
agents, including glucocorticoids, the endoplasmic reticu-
lum (ER) Ca2+-ATPase inhibitor thapsigargin and various
cancer therapeutic drugs, mobilize Ca2+ stores and trigger
apoptosis by early transient elevation of intracellular free
calcium ([Ca2+]i). However, elevation of [Ca2+]i has been
described also at later stages of the apoptotic process [1].
A number of calcium-mediated apoptosis signaling mech-
anisms have been described. Mitochondria are located in
microdomains close to Ca2+ channels of the ER where
cytosolic Ca2+ concentrations may become high on chan-
nel opening [2]. Mitochondrial Ca2+ uptake may result in
mitochondrial permeability transition, leading to mito-
chondrial swelling and apoptosis. The calpains, calcium-
activated cysteine proteases, have been implicated in
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apoptosis induction by some stimuli [3]. Calpain cleaves,
and thereby activates, a number of molecules that have
important functions in the apoptosis process, including
caspase-12 [4], Bax [5] and Bid [6]. Calmodulin (CaM) is
the major Ca2+ sensor of nonmuscle cells [7] and signaling
involving calmodulin has been implicated in apoposis
[8]. Different signaling mechanisms down-stream from
CaM are involved in various types of apoptotic responses,
including pathways involving calcineurin, DAP kinase
and calmodulin kinases. Calmodulin-dependent Kinase II
(CaMKII) has been found to be both pro-apoptotic [9-12]
and anti-apoptotic [13] in different studies.
The use of libraries of agents with diverse biological mech-
anisms allows for elucidation of new biological targets as
well as mechanisms relevant to tumor cell viability [14].
Many previous studies have identified compounds that
prevent the proliferation of tumor cells and several active
compounds have been developed into clinically effective
anticancer drugs. We here identified apoptosis-inducing
agents in a compound library prescreened for agents that
inhibit tumor cell proliferation. The objective of our study
was to use the different agents as bioprobes to investigate
the role of different calcium signaling mechanisms for
apoptosis signaling. Apoptosis induction was analyzed in
the presence and absence of a number of agents that influ-
ence Ca2+ signaling. The results show that most, but not
all, apoptotic drugs examined require calcium and that
CaMKII is an important mediator of apoptotic signaling.
Results
Identification of apoptosis-inducing agents by screening
The aim of this study was to investigate the importance of
different calcium pathways for induction of apoptosis of
tumor cells. Since our study required a wide variety of
apoptotic stimuli, we first set out to identify apoptosis-
inducing agents by screening a chemical library. The NCI
Mechanistic Drug Set, which contains 879 compounds
selected from approximately 40,000 compounds based
on different mechanisms of action with regard to cell
growth inhibition, was screened to identify mechanisti-
cally diverse apoptosis-inducing agents. Apoptosis-induc-
ing agents were identified using an assay which measures
the accumulation of a caspase-cleavage product of cytok-
eratin-18 (CK18) in cultures containing dying and dead
cells [15,16]; see Experimental procedures). Importantly,
this assay provides an integrative measure of apoptosis
and facilitates end-point measurements after treatment
with collections of drugs that induce apoptosis with dif-
ferent kinetics. We used the human colon carcinoma cell
line HCT116 as a screening target (p53wt; CK18+). Forty
agents ("bioprobes") that induce strong caspase-cleavage
activity were chosen based on representation of seven of
the nine different response areas of the 3d MIND self-
organizing maps [17]. Agents that segregate to the two
remaining response areas (both with uncharacterized
mechanisms) were not identified.
The 40 bioprobes were used at the lowest possible concen-
tration required for apoptosis induction. We first profiled
the pattern of signaling induced by these bioprobes using
four HCT116 cell lines which stably express different β-
lactamase reporters for 4 pathways relevant to apoptosis
signaling: p53, AP-1, NFAT and NF-κB (Fig. 1). AP-1
reporter induction was most frequently observed (30/40
compounds), whereas NFAT induction was most infre-
Activation of reporter constructs by pro-apoptotic com- pounds Figure 1
Activation of reporter constructs by pro-apoptotic 
compounds. Four different CellSensor® HCT116 cell lines 
(Invitrogen) were treated with 40 different pro-apoptotic 
compounds and stimulation of reporter activity measured at 
4 and 16 hours. Maximal stimulation at 4 or 16 hours time-
point is illustrated graphically (yellow squares: >2-fold activa-
tion; orange squares: >3-fold activation; red squares: >5-fold 
activation).
            2         3        5
 p53     AP-1    NFAT     NFkB       Compound
1
11
21
31
40BMC Chemical Biology 2008, 8:2 http://www.biomedcentral.com/1472-6769/8/2
Page 3 of 10
(page number not for citation purposes)
quent (5/40). A positive correlation was observed
between induction of the AP-1 and NF-κB reporters (p =
0.012; Fishers exact test). We conclude that the bioprobes
chosen on the basis of different mechanisms of growth
inhibition also induce a diverse pattern of signaling.
Examination of the role of calcium in apoptosis
We used the FLUO-4 fluorescent calcium indicator to
examine whether the bioprobes induced Ca2+ fluxes in
HCT116 cells. Twenty-seven of 40 (68%) bioprobes
induced >50% increases in Ca2+
(i) after 16 hours of expo-
sure (median 2.7-fold increase). Smaller increases in
Ca2+
(i) were observed after 3 and 7 hours of drug exposure
(Figure 2A). To examine the importance of calcium sign-
aling for induction of apoptosis, cells were treated with
the bioprobes in the presence or absence of the Ca2+ che-
lator BAPTA-AM [1,2-bis(2-aminophenoxy) ethane-
N,N,N1,N-tetra-acetic acid] followed by determination of
caspase-cleaved CK18. BAPTA-AM inhibited the genera-
tion of caspase-cleaved CK18 by the majority of the bio-
probes (Figure 2B). A median level of inhibition of
approximately 60% was observed (Figure 2B, inhibition
Investigating the importance of calcium signaling pathways for apoptosis Figure 2
Investigating the importance of calcium signaling pathways for apoptosis. (A) Increases in Ca2+
(i) evaluated by the 
fluorescent calcium indicator FLUO-4 after addition of the bioprobe set. Data in this and later figures are presented as box 
plots (median (25 – 75th percentile; 10th – 90th percentile)); (B) HCT116 cells were treated with the bioprobe set for 24 hours 
in the presence or absence of 10 μM BAPTA-AM. The generation of the apoptosis-specific caspase-cleavage product CK18-
Asp396 was assessed using the M30-Apoptosense® ELISA assay [15] and the degree of inhibition of caspase-cleavage was calcu-
lated for each compound; (C) Ca2+ is required during the late phase of apoptosis. BAPTA-AM was added at different times 
after addition of the bioprobe set and apoptosis was assessed at 24 hours of drug treatment; (D) Inhibiton of apoptosis by pre-
treatment with ryanodine (10 μM) or dantrolene (50 μM), (E; F) BAPTA-AM blocks drug-induced modulation of the conforma-
tion of Bak. (E) HCT116 cells were exposed to 8 different drugs in the presence or absence of BAPTA-AM. All 8 drugs induced 
FLUO-4 fluorescence and BAPTA-AM sensitive apoptosis. Fixed cells were stained with an antibody that recognizes an N-ter-
minal Bak epitope exposed after conformational activation during apoptosis [18,43]. (F) Inhibition of drug-induced caspase-3 
activation and Bak conformation by BAPTA-AM. Cells were exposed to one of the bioprobes (NSC106408), fixed and stained 
by an anti-Bak antibody and an antibody to active caspase-3.
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data for BAPTA-AM with regard to apoptosis induction by
all bioprobes is presented as a box plot (median and
spread)). Caspase-cleavage activity induced by some
agents were not affected at all, showing that Ca2+
(i) is not
required for all types of apoptotic stimuli. Furthermore,
induction of caspase-cleavage activity by thapsigargin (a
SERCA pump inhibitor and inducer of ER stress) was
inhibited by 85%.
BAPTA-AM could be added as late as 7 hours after drug
addition and still provide significant protection from
apoptosis (Figure 2C). Apoptosis was inhibited by block-
ing the ryanodine receptor (RyR) and inositol 1,4,5-tri-
phosphate (InsP3) receptors using ryanodine and
dantrolene, respectively (Fig. 2D). These results show that
Ca2+ is required for full induction of caspase-cleavage
activity by many bioprobes but that Ca2+ is not a manda-
tory requirement for all apoptotic signals. Results were
validated by analysis of caspase-3 activity (for an example,
see Figure 2F), loss of mitochondrial membrane potential
(not shown) and activation of the conformation of the
pro-apoptotic mitochondrial protein Bak (see below).
Many apoptotic signals involve the mitochondria, leading
to release of molecules such as cytochrome c and AIF from
mitochondria to the cytosol. The Bak and Bax proteins are
essential regulators of mitochondrial permeabilization.
Activation of Bak during apoptosis results in an altered
molecular conformation, leading to altered conformation
of the N-terminus of the protein [18]. BAPTA-AM was
found to inhibit the conformational change of Bak after
addition of 8 agents that showed calcium-dependent
apoptosis induction (Figure 2E, F). We conclude from
these experiments that calcium signaling is required at a
late stage during apoptosis, but prior to conformational
activation of Bak.
Importance of calmodulin for drug-induced apoptosis
We examined the relative roles of three processes known
to be potentially involved in calcium-regulated apoptosis:
mitochondrial calcium uptake, activation of the protease
calpain and signaling involving calmodulin. Ruthenium
red is a non-competitive inhibitor of the mitochondrial
Ca2+ uniporter [19], used to inhibit mitochondrial cal-
cium uptake in cells [20,21]. Ruthenium red was found to
inhibit apoptosis induced by some agents, but did not
affect apoptosis induced by the majority of bioprobes
(median level of inhibition: 0%; Figure 3A). Calpain is a
Ca2+-activated protease involved in apoptosis signaling
[5,6,22]. Calpeptin is a membrane-permeable inhibitor of
both  μ-calpain and m-calpain [3]. Calpeptin showed
some inhibitory activity of apoptosis (Figure 3A), and
increased calpain activity was accordingly detected after
treatment with calpeptin-sensitive agents (Figure 3B).
However, the median level of inhibition of caspase-
cleaved CK18 was only one fourth of that observed using
BAPTA-AM (15% versus 60%). We finally examined cal-
modulin, a central regulator of cellular Ca2+ responses. We
found that the calmodulin inhibitor W7 was more effec-
tive than calpeptin in inhibiting apoptosis, generating a
median level of inhibition of 24% (Figure 3A).
Relative importance of calmodulin-regulated pathways
The finding that W7 inhibited apoptosis by several drugs
prompted us to examine the potential involvement of dif-
ferent calmodulin-regulated pathways. Calcineurin
(PP2B) is a Ca2+/calmodulin activated serine/threonine-
specific phosphatase implicated in apoptotic signaling
[23]. Calcineurin dephosphorylates NFAT, resulting in
nuclear translocation and gene activation [24]. The antibi-
otic FK506 binds FKBP-12 and the resulting [FK506-
FKBP-12] complex inhibits calcineurin activity [25].
FK506 did not significantly inhibit apoptosis induction
by the bioprobe set (Figure 4A). We also examined the
possible role of death-associated protein kinase (DAPK),
a Ca2+/calmodulin-regulated protein kinase implicated
in cell death [26]. Down-regulation of DAPK expression
by siRNA did not significantly affect apoptosis induced by
the bioprobe set (Fig. 4A), consistent with previous find-
ings [27].
Other calmodulin-induced signaling pathways linked to
apoptosis signaling involve calmodulin kinases. CAMKK-
β was recently implicated in induction of macro-
autophagy [28]. The CAMKK inhibitor STO-609 had a
modest inhibitory effect on apoptosis (Figure 4A). CaM-
KII has been implicated in apoptosis by some stimuli
[9,10,12]. Interestingly, the CaMKII inhibitor KN-93
reduced apoptosis to a similar degree as W7 (Figure 4A).
Furthermore, treatment with CaMKII siRNA inhibited
apoptosis induced by some examined compounds (Fig.
4B). Increases in CaMKII activity were observed after treat-
ment by a number of compounds at 18 hours of treatment
(Figure 4C). These results suggested that a pathway
involving CaMKII is important in calcium-mediated
apoptotic signaling down-stream of CaM.
Role of CaMKII in apoptotic signaling
The experiments presented so far used the entire set of 40
bioprobes to examine to which extent different inhibitors
affected apoptosis induction. This approach could not be
used to specifically study a single pathway, since many of
the compounds would be irrelevant. To specifically study
CaMKII dependent apoptosis we chose the plant sesquit-
erpene lactone helenalin (NSC85236) which showed KN-
93 sensitive apoptosis and that induced CaMKII activity.
The selection was also supported by a previous report that
helenalin causes increases in [Ca2+]i in 3T3 cells [29].
Importantly, in contrast to other candidates considered,
helenalin has not been reported to induce reactive oxygenBMC Chemical Biology 2008, 8:2 http://www.biomedcentral.com/1472-6769/8/2
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species or DNA damage. Others have, however, described
helenalin as a specific inhibitor of NF-κB at 10 μM [30].
We here used helenalin at a concentration of 2 μM (see
Discussion).
Calcium signaling via CaMKII activates apoptosis signal-
ing kinase 1 (ASK-1) [31,32]. ASK-1 is a serine/threonine
protein kinase capable of activating the pro-apoptotic JNK
pathway. HCT116 cells were treated with 2 μM helenalin
and ASK-1 kinase activity was measured using an in vitro
immunokinase assay with p38 as a substrate. Stimulation
of ASK-1 activity was observed at 16 hours of treatment
(Figure 5A; top panel). ASK-1 has been reported to be acti-
vated by calcium signaling [31,32], but there are few
reports linking calcium signaling to JNK activation during
apoptosis. We found that helenalin had induced JNK
activity at 16 hours of treatment, assessed by an immu-
nokinase assay (Figure 5A; bottom panel). In order to
determine whether ASK-1 is required for helenalin-
induced apoptosis, HCT116 cells were transfected with a
dominant negative mutant of ASK-1. Strong inhibition of
apoptosis was observed (Figure 5B). Furthermore, the JNK
inhibitor SP600125 inhibited helenalin-induced apopto-
sis. Addition of the JNK inhibitor at 7 hours of drug treat-
Involvement of mitochondrial calcium uptake, calpain and calmodulin for apoptosis induction Figure 3
Involvement of mitochondrial calcium uptake, calpain and calmodulin for apoptosis induction. (A) Inhibition of 
generation of the caspase-cleaved CK18-Asp396 fragment by ruthenium red (5 μM), calpeptin (10 μM) or W7 (10 μM). 
HCT116 cells were individually treated with the 40 bioprobes in the presence inhibitors and CK18-Asp396 levels were deter-
mined by the M30-Apoptosense® ELISA assay. Shown are median levels of inhibition for all 40 agents; (B) Induction of calpain 
activity of agents that showed calpeptin-sensitive apoptosis. Enzyme activity was measured after 18 hours using apoptosis-
inducing drug concentrations.
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ment was sufficient for inhibition of apoptosis (Figure
5C). The observation of a late requirement for JNK is con-
sistent with a late requirement for calcium and of an
apoptosis-specific role for sustained JNK. Helenalin did
not induce phosphorylation of p38 and apoptosis was not
inhibited by the p38 kinase inhibitor SB203580 (not
shown; etoposide was used as a positive control).
The levels of ASK-1 and JNK kinase activation by helenalin
were moderate and the precision of the in vitro kinase
assays was not found sufficient to reliably determine
whether these kinases were inhibited by BAPTA-AM and
KN-93. We therefore used the AP-1 reporter HCT116 cell
line described in Fig. 1. Stimulation with phorbol ester
and thapsigargin induced a reproducible increase in
reporter activity (6.9-fold; C.V.: 17%). Helenalin induced
a reproducible 2-fold induction of the AP-1 reporter at 18
hours of treatment (Fig. 5D). Reporter activity represents
JNK activity since stimulation was decreased by the JNK
inhibitor SP600125, but not by the ERK inhibitor
PD98059. Using this assay we found that both BAPTA-AM
and KN-93 inhibited helenalin-induced activation of the
AP-1 reporter (Fig. 5D), showing that helenalin-induced
AP-1 activity is dependent on calcium signaling.
Discussion
Single-drug studies are limited with regard to the informa-
tion about the relative contribution of various pathways
to apoptosis. We here used a collection of 40 small molec-
ular agents to induce apoptosis. These agents were
selected from a larger drug set compiled on the basis of
different mechanisms of growth inhibition of the NCI 60
cell line panel. Studies using a set of reporter cell lines
confirmed that these compounds induced different pat-
terns of signaling. This approach allowed a comprehen-
sive evaluation of the role of calcium signaling in
apoptosis. The data show that for many types of stimuli,
calcium is generally required late during apoptosis induc-
tion. Calcium was likely to be released from intracellular
stores, as evidenced by our finding that apoptosis was
inhibited by blocking the ryanodine receptor (RyR) and
the inositol 1,4,5-triphosphate (InsP3) receptor.
Of the calcium-regulated mechanisms examined, calmod-
ulin-regulated pathways appeared to be most important
for induction of apoptosis. Calmodulin has previously
been implicated in apoptosis, both as a pro-survival [33]
and as a pro-apoptotic factor [8]. CaMKII is a major medi-
ator of cellular Ca2+ effects and inhibition of this kinase
Role of calmodulin signaling in apoptosis induction Figure 4
Role of calmodulin signaling in apoptosis induction. (A) Inhibition of caspase-cleavage activity by W7 (10 μM), the cal-
cineurin inhibitor FK506 (10 μM), STO-609 (25 μM), KN-93 (10 μM) or DAPK siRNA. The efficiency of siRNA transfection on 
down-regulation was verified by western blotting. Inhibition of generation of CK18-Asp396 was calculated as in Fig. 3A; (B) 
Inhibition of caspase-cleavage activity by CaMKII siRNA. Cells were transfected with siRNA to CaMKII and exposed to the 
compounds indicated. CK18-Asp396 levels were determined by the M30-Apoptosense® ELISA assay. Filled bars; control 
siRNA; open bars: CaMKII siRNA; (C) CaMKII enzymatic activity at 18 hours after treatment with selected compounds.
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was here found to inhibit apoptosis to a greater extent
than inhibition of other candidates such as calpain and
calcineurin/PP2B. The biological actions of CaMKII have
been studied in most detail in intermediate metabolism
and neural signaling [34]. CaMKII has been reported to be
activated downstream of protease activation in apoptosis
induced by UV light and TNF [9]. Induction of apoptotic
cell death in hepatocytes by the toxin microcystin can be
blocked by CaMKII inhibitors [10]. Furthermore, cad-
mium induces CaMKII and cadmium-induced apoptosis
is dependent on this kinase [12]. Our data support these
previous studies and suggest a common role for CaMKII
in apoptosis by a number of different stimuli.
Other calmodulin-regulated pathways that were consid-
ered involved calcineurin and death-associated protein
kinase (DAPK). Calcineurin is a widely expressed protein
phosphatase regulated by Ca2+/calmodulin. Calcineurin
dephosphorylates the NFAT transcription factor, resulting
in nuclear translocation and gene activation [24]. Overex-
pression of calcineurin leads to apoptosis in cells deprived
of growth factors [35]. Calcineurin dephosphorylates the
pro-apoptotic Bcl-2 family protein BAD, leading to trans-
location of BAD to mitochondria [36]. Calcineurin has
been implicated in p53-mediated apoptosis of colon car-
cinoma cells as down-stream mediator of calcium released
from intracellular stores through the generation of reac-
tive oxygen species [37]. Calcineurin did not appear to an
important role for apoptosis induced by the set of bio-
probes studies here, and we only found weak induction of
NFAT. DAPK is a Ca2+/calmodulin-regulated protein
kinase that mediates cell death [26]. There is little evi-
dence in the literature that DAPK signaling is important
for drug- or radiation-induced apoptosis of tumor cells
[27]. We did not find any significant effect of DAPK down-
regulation by siRNA on apoptosis induced by the bio-
probe set.
Sustained JNK activation is recognized as a hallmark of
many apoptotic processes [38]. Sustained JNK activation
has been demonstrated to be associated with repression of
the JNK-phosphatase MKP1 [39] but is also believed to be
Involvement of ASK-1 and JNK in helenalin-induced apoptosis Figure 5
Involvement of ASK-1 and JNK in helenalin-induced apoptosis. (A) HCT116 cells were treated with 2 μM helenalin 
for 16 hours and ASK-1 activity (upper panel) or JNK activity (lower panel) was determined by immunokinase assays. (B) Cells 
were transfected with a dominant negative mutant of ASK-1 (black bars) or a control plasmid (open bars) and active caspase-3 
was determined. The ASK-1 construct was HA-tagged and cells were stained with antibodies to HA and active caspase-3 fol-
lowed by analysis by flow cytometry; (C) HCT116 cells were treated with 2 μM helenalin. SP600125 (5 μM) was added at the 
times indicated and apoptosis was assessed at 24 hours of drug treatment. The experiment was repeated with similar results. 
(D) Activation of an AP-1 reporter construct by helenalin. The CellSensor AP-1-bla HCT116 cell line (Invitrogen) was treated 
with 2 μM helenalin in the presence or absence of the indicated inhibitors. Activity was determined after 18 hours. Statistical 
significance is indicated relative to helenalin-only-treated cells (* p < 0.02; ** p < 0.002; Student's t-test).
 A                             B                                                   C                                                             D               
                 CTR           HEL
          20
TIME OF ADDITION OF SP600125
(HOURS)
                  0         2        5        7       16
100
80
60
40
20
P
E
R
C
E
N
T
 
I
N
H
I
B
I
T
I
O
N
P
E
R
C
E
N
T
 
C
A
S
P
A
S
E
-
3
 
P
O
S
I
T
I
V
E
 
C
E
L
L
S
                25
                   5
                10
                15
CTR  HEL
CTR  HEL
P -p38
P -JUN
                      CTR           HELENALIN
                2.5
                   0.5
                1.0
                1.5
          2.0
A
P
-
1
 
R
E
P
O
R
T
E
R
 
A
C
T
I
V
I
T
Y
* *
* *
 
 
 
 
 
 
 
-
S
P
6
0
0
1
2
5
P
D
9
8
0
5
9
B
A
P
T
A
-
A
M
K
N
-
9
3
     CTR   HELBMC Chemical Biology 2008, 8:2 http://www.biomedcentral.com/1472-6769/8/2
Page 8 of 10
(page number not for citation purposes)
due to increased de novo phosphorylation by uncharac-
terized signaling pathways [40]. It is known that the cal-
cium ionophore ionomycin induces JNK activity [41], but
a role of calcium signaling for sustained JNK activation is
not generally accepted. It is conceivable that calcium sign-
aling contributes to apoptosis-specific sustained JNK acti-
vation via CaMKII. Of the different inhibitors that we have
tested for inhibition of apoptosis by the current bioprobe
set, BAPTA-AM and the JNK inhibitor SP600125 have pro-
vided the strongest degree of protection (median inhibi-
tion approximately 60% by BAPTA-AM; median
inhibition 30% by SP600125). Other agents that we have
been tested are the superoxide scavenger Tiron and the
p38 kinase inhibitor SB203580, both of which were
found to be less effective (MHO and AMH, unpublished
data). JNK activation and calcium signaling pathways are
likely to be of fundamental importance for apoptosis
induced by many signals. That calcium signaling may be
important for JNK activation is therefore an attractive pos-
sibility, but has not been as extensively studied as for
example JNK activation by reactive oxygen/nitrogen spe-
cies [42].
Small molecules are powerful tools for charting signaling
pathways. It is, however, important to bear in mind that
small molecules rarely affect single targets. This compli-
cates the interpretation of the mechanism(s) of action of
e.g. anticancer drugs. In the present study, we used the
plant sesquiterpene helenalin to study the role of CaMKII
in apoptosis and found that helenalin induced CaMKII,
ASK-1 and JNK and that inhibiton of these kinases inhib-
its apoptosis. Helenalin may, however, have other effects
and has in fact previously been described as a specific
inhibitor of NF-kB when used at 10 μM [30]. We here used
helenalin at 2 μM and did not observe NF-κB inhibition
at this concentration (not shown). In fact, we have earlier
found that when used at 10 μM, the response to helenalin
was found to shift from apoptosis to necrosis [16].
Conclusion
A number of calcium-regulated apoptosis pathways have
been identified in various studies. Using a chemical biol-
ogy approach with high throughput potential we have
here both demonstrated a strategy for pathway charting as
well as demonstrated an important role for CaMKII in
apoptosis signaling in a human carcinoma cell line. Our
data raise the possibility that calcium signaling is involved
in sustained JNK activation during apoptosis induced by
different stimuli.
Methods
Materials
The Mechanistic Drug Set was kindly provided by the
Developmental Therapeutics Program, the National Can-
cer Institute, Bethesda, MD. This library contains 879 sub-
stanses that inhibit cell proliferation and/or induce cell
death. The following compounds were identified to
induce apoptosis by screening and chosen for the present
study: NSC number: 622627 (4.0 μM), 69187 (7.0 μM),
10010 (4.0 μM), 285116 (2.0 μM), 647889 (6.0 μM),
157389 (7.0 μM), 24819 (1.0 μM), 13973(7.0 μM),
140377 (1.0 μM), 72961 (4.0 μM), 313981 (2.0 μM),
651079 (1.0 μM), 106408 (0.3 μM), 267461 (0.5 μM),
24818 (0.1 μM), 85236 (2.0 μM), 102811 (2.0 μM),
18268 (0.5 μM), 89671 (2.0 μM), 219734 (10.0 μM),
337766 (7.0 μM), 638646 (5.0 μM), 651080 (7.0 μM),
44690 (7.0 μM), 78365 (5.0 μM), 102866 (0.5 μM),
104129(10.0 μM), 164914 (1.0 μM), 258812 (0.2 μM),
407806 (1.0 μM), 635448 (2.0 μM), 673622 (1.0 μM),
679524 (2.0 μM), 684480 (7.0 μM), 328587 (5.0 μM),
693632 (2.0 μM), 175634 (5.0 μM), 68093 (5.0 μM),
4857 (0.2 μM) and 30916 (1.0 μM). These agents segre-
gate into 7 of 9 possible response categories when tested
on the NCI 60 cell line panel (see [17]): mitosis (M): 6
agents; membrane function (N): 7 agents; nucleic acid
metabolism (S): 9 agents; metabolic stress and cell sur-
vival (Q): 8 agents; kinases/phosphatases and oxidative
stress (P): 7 agents; uncharacterized regions R, F, J, and V:
0, 2, 0 and 3 agents. Compounds were stored in 100%
DMSO in 96-well plates and added to cells using an
EpMotion robot system (Eppendorf Nordic, Horsholm,
Denmark). A final concentration of 0.5% DMSO was
achieved in the cell cultures; control cultures were treated
with this concentration.
Cell culture
HCT116 colon carcinoma (p53wt) were generously pro-
vided by Dr. Bert Vogelstein and were maintained in
McCoy's 5A modified medium supplemented with 10%
foetal calf serum, L-glutamate, penicillin and streptomy-
cin at 37°C in 5% CO2. Tissue culture reagents were
obtained from Gibco Cell Culture Products. Transfection
was performed using Lipofectamine 2000 (Invitrogen,
Carlsbad, Cal) and 2 μg dnASK-1 mutant. DAP kinase
siRNA was obtained from Qiagen (Hilden, Germany) and
down-regulation was examined by western blotting.
Reporter cell lines
Stable reporter HCT116 cell lines (CellSensor®) were
obtained from Invitrogen (Carlsbad, CA). β-lactamase
activity was determined using GeneBLAzer®  substrates
from Invitrogen. β-lactamase activity leads to emission of
blue light from the coumarin at 447 nm which was
recorded in a Tecan Infinite F200 reader.
Assessment of apoptosis
The accumulation of caspase-cleaved cytokeratin-18
(CK18-Asp396) was determined by the M30-Apopto-
sense® ELISA assay [15] (PEVIVA AB, Bromma, Sweden).
Cells were seeded at 104/well in 96-well plates the dayBMC Chemical Biology 2008, 8:2 http://www.biomedcentral.com/1472-6769/8/2
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before treatment and treated with drugs as indicated. At
the end of the incubation period, NP40 was added to the
tissue culture medium to 0.1% and 25 μl of the content of
each well (including activity released to the medium from
attached and floating cells and cell fragments) was
assayed for caspase-cleaved CK18. Activation of caspase-3
was investigated using an antibody specific for the active
form of the enzyme. Paraformaldehyde fixed cells
(0.25%, 5 min) were washed three times with PBS and
incubated for 60 min with a fluorescein isothiocyanate-
conjugated antibody recognizing active caspase-3 (BD
Biosciences Pharmingen, San Diego, Cal). The antibody
was diluted 1:50 in PBS containing digitonin (100 μg/
ml). After incubation, the cells were washed with PBS, and
fluorescence was monitored using the FL1 channel of a
FACScalibur flow cytometer (BD, Franklin Lakes, NJ).
Upon induction of apoptosis, the proapoptotic Bak pro-
tein undergoes a conformational change that exposes an
otherwise inaccessible N-terminal epitope [18]. We used
an antibody shown to specifically recognize this epitope
(amino acids 1 to 52 of Bak; EMD Chemicals, La Jolla,
Cal). The increases in accessibility of the epitope were
monitored by flow cytometry as previously described
[43]. Data are presented as fold increase in immunofluo-
rescence from control levels.
Measurement of Ca2+
(i)-
Drug-treated cells were harvested with cell dissociation
solution (Sigma Aldrich, St Louis, MO) and the sus-
pended cells were then incubated with the Ca2+ indicator
FLUO-4 (Molecular Probes, Invitrogen) for 60 s. The
intracellular Ca2+ levels, seen as fluorescent signal, were
then assessed by flow cytometry using the FL1 channel.
Enzyme activity measurements
CaMKII activity was assayed in cell extracts using the
PROMEGA SignaTECT® Assay which utilizes a specific
biotinylated peptide substrate. Cells were harvested,
washed with PBS and resuspended in Extraction buffer
(50 mM HEPES pH 7.5, 5 mM EDTA, 1 mM Na-
orthovanadate, 1 mM PMSF, Protease Coctail (1:50,
Sigma Aldrich). Cells were lysed by four cycles of freeze-
thawing in liquid nitrogen. Lysates were centrifuged
(16,000 × g; 20 min) and supernatant fractions were col-
lected. Enzymatic activity was assayed according to manu-
facturer's instructions. Calpain activity was assayed in cell
extracts using the Calbiochem®  Calpain Activity Kit
according to manufacturer's instructions. The data
obtained were calculated as relative fluorescence units
(RFU) and presented as fold untreated control.
Immunokinase assays
The immunokinase assay for ASK-1 was performed as
described [44]. In brief, immunoprecipitated ASK-1 was
first incubated with GST-MKK6 (Jena Bioscience, Ger-
many). The activated complex was then incubated with
0.3 mCi [γ-32P]ATP and 1 μg p38aHis (inactive; Jena Bio-
science). After incubation for 10 min at room tempera-
ture, the reaction was terminated by addition of SDS-DTT
and boiling. Thereafter samples were subjected to SDS-
PAGE, followed by autoradiography. The immunokinase
assay for JNK1-2 was performed after extraction in lysis
buffer (RIPA buffer containing protease inhibitor cocktail
(Sigma Aldrich), 1 mM PMSF, 2 mM DTT and 0.1 mM Na-
orthovanadate). JNK1-2 were immunoprecipitated from
cell extracts and the resulting immunocomplexes were
bound to Protein A-Sepharose beads [45]. Beads were
then resuspended in 20 mM HEPES pH 7.6, 2 mM DTT,
20 mM MgCl2, 1 mM PMSF, 0.1 mM Na-orthovanadate)
containing 10 μM unlabeled ATP, 5 μCi, (γ-32P)ATP and 1
μg of recombinant GST-c-Jun and incubated at 30°C for
20 minutes. The reaction was terminated by addition of
SDS-DTT and boiling. Thereafter samples were subjected
to SDS-PAGE, followed by autoradiography.
Statistics
Most of the data generated was not normally distributed
and is presented as median (box plot; 25 – 75th percentile;
10th – 90th percentile). The Wilcoxon two-sample test was
used to compare levels between samples.
Abbbreviations
CaM: Calmodulin; CaMKII: Calmodulin-dependent
Kinase II ; RyR: Ryanodine receptor; InsP3: Inositol 1,4,5-
triphosphate;  DAPK: Death-associated protein kinase;
ASK-1: Apoptosis signaling kinase 1; TNF: Tumor necrosis
factor;  NFAT: Nuclear factor of activated T-cells.
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